prepar
threedimension
model
aka
proteas
use
crystal
structur
highli
similar
ident
ortholog
sarscov
residu
involv
catalysi
substrat
bind
dimeris
conserv
comparison
polyprotein
sequenc
show
ident
cleavag
site
coronavir
polyprotein
highli
conserv
base
nearident
substrat
specif
high
sequenc
ident
opinion
previou
progress
specif
inhibitor
develop
sarscov
enzym
confer
counterpart
molecular
model
perform
virtual
screen
purchas
drug
propos
candid
consider
among
antivir
ledipasvir
velpatasvir
particularli
attract
therapeut
combat
new
coronaviru
minim
side
effect
commonli
fatigu
headach
drug
epclusa
velpatasvirsofosbuvir
harvoni
ledipasvirsofosbuvir
could
effect
owe
dual
inhibitori
action
two
viral
enzym
cite
articl
predict
proteas
structur
virtual
screen
reveal
velpatasvir
ledipasvir
drug
repurpos
candid
version
peer
review
approv
http
doipubm
abstract
publish
full
text
muramatsu
takemoto
c
kim
yt
et
al
sarscov
proteas
cleav
ctermin
autoprocess
site
novel
subsit
cooper
proc
natl
acad
sci
u
pubm
abstract
publish
full
text
free
full
text
krivov
gg
shapovalov
mv
dunbrack
rl
jr
improv
predict
protein
sidechain
conform
protein
pubm
abstract
publish
full
text
free
full
text
cm
rey
j
lagorc
et
al
mtiopenscreen
web
server
structurebas
virtual
screen
nucleic
acid
re
pubm
abstract
publish
full
text
free
full
text
trott
olson
aj
autodock
vina
improv
speed
accuraci
dock
new
score
function
effici
optim
multithread
j
comput
chem
pubm
abstract
publish
full
text
free
full
text
pymol
molecular
graphic
system
llc
refer
sourc
chen
yw
model
screen
http
huang
c
wei
p
fan
k
et
al
proteinas
sar
coronaviru
catalyz
substrat
hydrolysi
gener
base
mechan
biochemistri
pubm
abstract
publish
full
text
hsu
mf
kuo
cj
chang
kt
et
al
mechan
matur
process
sarscov
proteas
j
biol
chem
pubm
abstract
publish
full
text
barrila
j
bacha
u
freir
e
longrang
cooper
interact
modul
dimer
sar
pro
biochemistri
pubm
abstract
publish
full
text
free
full
text
barrila
j
gabelli
sb
bacha
u
et
al
mutat
disrupt
dimer
enzymat
activ
sar
pro
biochemistri
pubm
abstract
publish
full
text
free
full
text
hu
zhang
li
l
et
al
two
adjac
mutat
dimer
interfac
sar
coronaviru
proteas
caus
differ
conform
chang
crystal
structur
virolog
pubm
abstract
publish
full
text
chen
zhang
j
hu
et
al
residu
dimer
interfac
sar
coronaviru
proteas
dimer
stabil
character
enzym
catalyt
activ
analysi
j
biochem
pubm
abstract
publish
full
text
ju
j
kumara
li
x
et
al
nucleotid
analogu
inhibitor
viral
polymeras
biorxiv
publish
full
text
lovel
sc
word
jm
richardson
js
et
al
penultim
rotam
librari
protein
pubm
abstract
publish
full
text
pillaiyar
manickam
namasivayam
v
et
al
overview
sever
acut
respiratori
syndromecoronaviru
sarscov
proteas
inhibitor
peptidomimet
small
molecul
chemotherapi
j
med
chem
pubm
abstract
publish
full
text
kuo
cj
liang
ph
character
inhibit
main
proteas
sever
acut
respiratori
syndrom
coronaviru
chembioeng
review
publish
full
text
chu
cm
cheng
vc
hung
et
al
role
lopinavirritonavir
treatment
sar
initi
virolog
clinic
find
thorax
pubm
abstract
publish
full
text
free
full
text
stockman
lj
bellami
r
garner
p
sar
systemat
review
treatment
effect
plo
med
pubm
abstract
publish
full
text
free
full
text
gruber
c
steinkelln
g
coronaviru
formerli
known
wuhan
coronaviru
find
structur
bioinformat
level
refer
sourc
dayer
mr
talebgassabi
dayer
ms
lopinavir
potent
drug
coronaviru
infect
insight
molecular
dock
studi
arch
clin
infect
di
publish
full
text
nukoolkarn
v
lee
vs
malaisre
et
al
molecular
dynam
simul
analysi
ritonavir
lopinavir
sarscov
pro
inhibitor
j
theor
biol
pubm
abstract
publish
full
text
zhang
xw
yap
yl
old
drug
lead
compound
new
diseas
bind
analysi
sar
coronaviru
main
proteinas
hiv
psychot
parasit
drug
bioorg
med
chem
pubm
abstract
publish
full
text
wu
cy
jan
jt
sh
et
al
small
molecul
target
sever
acut
respiratori
syndrom
human
coronaviru
pubm
abstract
publish
full
text
free
full
text
dyall
j
coleman
cm
hart
bj
et
al
repurpos
clinic
develop
drug
treatment
middl
east
respiratori
syndrom
coronaviru
infect
antimicrob
agent
chemoth
pubm
abstract
publish
full
text
free
full
text
holshu
ml
debolt
c
lindquist
et
al
first
case
novel
coronaviru
unit
state
n
engl
j
med
pubm
abstract
publish
full
text
xu
z
peng
c
shi
et
al
nelfinavir
predict
potenti
inhibitor
main
proteas
integr
approach
combin
homolog
model
molecular
dock
bind
free
energi
calcul
biorxiv
publish
full
text
liu
x
wang
xj
potenti
inhibitor
coronaviru
proteas
clinic
approv
medicin
biorxiv
publish
full
text
stoermer
mj
homolog
model
wuhan
coronaviru
pro
proteas
chemrxiv
publish
full
text
januari
new
coronaviru
offici
name
implic
alarm
outbreak
pneumonialik
ill
origin
wuhan
citi
hubei
china
humantohuman
transmiss
first
confirm
guangdong
china
world
health
organis
declar
global
public
health
emerg
februari
confirm
case
report
death
toll
height
crisi
viru
spread
rate
scale
far
wors
previou
coronavir
epidem
immedi
evid
genom
coronaviru
evolutionarili
relat
ident
betacoronaviru
implic
sever
acut
respiratori
syndrom
sar
origin
bat
caus
global
outbreak
momentum
research
develop
antivir
agent
sarscov
carri
epidem
subsid
despit
sar
treatment
yet
come
fruition
howev
knowledg
acquir
extens
research
develop
effort
may
use
inform
current
therapeut
option
viral
genom
encod
protein
among
two
proteas
pl
pro
pro
vital
viru
replic
cleav
two
translat
polyprotein
individu
function
compon
proteas
pro
aka
main
proteas
pro
consid
promis
drug
target
tremend
effort
spent
studi
protein
order
identifi
therapeut
sarscov
particular
pathogen
coronavirus
eg
merscov
middl
east
respiratori
syndrom
coronaviru
gener
share
similar
activ
site
enzymat
mechan
purpos
studi
build
molecular
model
pro
carri
virtual
screen
identifi
readili
usabl
therapeut
intent
howev
comment
structurebas
drug
design
research
time
current
epidem
translat
polyprotein
sequenc
obtain
annot
genbank
entri
genom
access
number
compar
sequenc
sarscov
sequenc
access
number
proteas
cleavag
site
matur
protein
sequenc
obtain
sequenc
comparison
align
perform
blastp
highresolut
apoenzym
structur
sarscov
pro
pdbid
employ
templat
variant
residu
mutat
silico
follow
manual
adjust
ensur
best
sidechain
rotam
employ
tabl
rebuilt
model
subject
steepest
descent
energi
minimis
gromac
use
gromo
forcefield
restraint
forc
constant
kj
mol
nm
appli
backbon
atom
atom
vital
residu
tabl
access
surfac
area
residu
calcul
areaimol
suit
mtiopenscreen
web
servic
use
screen
librari
purchas
drug
drugslib
bind
site
grid
specifi
activesit
residu
activ
site
chain
chain
b
screen
independ
autodock
vina
crystal
structur
releas
strip
inhibitor
subject
screen
list
target
ligand
dock
combin
rank
bind
energi
produc
screen
top
rank
use
bind
energi
cutoff
hit
chain
b
examin
visual
pymol
version
earlier
version
articl
found
chemrxiv
doi
first
avail
genom
genbank
ncbi
refer
sequenc
sequenc
extract
align
sarscov
overal
aminoacid
sequenc
ident
high
conserv
notic
polyprotein
cleavag
site
pro
site
highli
conserv
ident
extend
data
tabl
infer
respect
proteas
similar
specif
pro
sequenc
residu
differ
sarscov
ident
compar
polyprotein
pro
sequenc
among
genom
genbank
model
pro
amino
acid
known
import
enzym
function
list
tabl
unexpectedli
none
variant
posit
involv
major
role
therefor
confid
prepar
structur
model
pro
molecular
model
extend
data
figur
immedi
use
silico
develop
target
treatment
submit
first
draft
studi
crystal
structur
pro
solv
releas
pdb
id
confirm
predict
model
good
within
experiment
error
extend
data
figur
examin
molecular
graphic
solut
found
fit
respect
activ
site
convincingli
bind
energi
chain
complex
gener
higher
chain
b
approxim
kcal
mol
tabl
presum
demonstr
intrins
conform
variabl
aand
bchain
activ
site
crystal
structur
averag
rootmeansquar
deviat
rmsd
atom
posit
activesit
residu
screen
differ
bind
energi
small
suggest
rank
discriminatori
top
scorer
examin
combin
two
screen
found
candid
give
promis
bind
model
etoposid
phosphat
count
one
tabl
check
action
target
side
effect
candid
among
first
notic
velpatasvir
figur
ledipasvir
inhibitor
protein
hepat
c
viru
hcv
market
approv
drug
combin
sofosbuvir
prodrug
nucleotid
analogu
inhibitor
rnadepend
rna
polymeras
rdrp
interestingli
sofosbuvir
recent
propos
antivir
base
similar
replic
mechan
hcv
coronavirus
result
strengthen
dualcompon
hcv
drug
epclusa
velpatasvirsofosbuvir
harvoni
ledipasvirsofosbuvir
may
attract
candid
repurpos
may
inhibit
two
coronavir
enzym
drug
target
two
viral
protein
substanti
reduc
abil
viru
develop
resist
directact
antivir
drug
also
associ
minim
side
effect
conveni
oral
administ
tabl
flavonoid
glycosid
diosmin
figur
hesperidin
figur
obtain
citru
fruit
fit
well
block
substrat
bind
site
yet
compound
tabl
silico
mutagenesi
pro
variant
residu
refer
sarscov
enzym
shown
respect
treatment
rotam
b
refer
individu
chain
dimer
model
chain
crystal
asymmetr
unit
ident
rotam
symbol
bracket
defin
accord
convent
richardson
follow
respect
rank
popular
asa
access
surfac
area
averag
b
chain
residu
sarscov
pro
structur
rel
asa
residu
x
glyxgli
conform
residu
rotam
asa
remark
replac
tabl
hesperidin
hit
show
multipl
time
suggest
mani
mode
bind
figur
teniposid
etoposid
phosphat
chemic
relat
turn
multipl
hit
good
bind
model
figur
howev
chemotherapi
drug
lot
strong
side
effect
need
intraven
administr
tabl
approv
drug
venetoclax
figur
investig
drug
score
well
screen
venetoclax
anoth
chemotherapi
drug
burden
side
effect
includ
upper
respiratori
tract
infect
tabl
much
disclos
subject
crystal
structur
virtual
screen
procedur
similar
list
candid
show
consist
extend
data
tabl
high
score
although
ledipasvir
found
notic
compound
list
molecular
weight
mw
except
lumacaftor
largest
one
ledipasvir
size
peptid
substrat
deepli
buri
proteas
activ
site
demand
larg
molecul
mani
rotat
dynam
fit
identifi
five
trial
clinicaltrialsgov
involv
antivir
immunomodulatori
drug
treatment
sar
one
record
receiv
lot
attent
amid
current
outbreak
lopinavirritonavir
combin
proteas
inhibitor
origin
develop
hiv
sar
outbreak
despit
lack
clinic
trial
tri
emerg
measur
found
offer
improv
clinic
outcom
howev
scientist
express
sceptic
analog
compound
specul
act
sarscov
pro
specif
yet
crystal
structur
support
although
dock
studi
carri
propos
variou
bind
mode
ic
valu
lopinavir
k
ritonavir
establish
although
far
cure
base
result
two
cov
pro
enzym
ident
far
protein
sequenc
substrat
specif
concern
opinion
still
one
recommend
rout
immedi
treatment
time
write
earli
februari
look
beyond
pro
earlier
screen
produc
candid
could
repurpos
sarscov
merscov
addit
coronavir
protein
could
target
screen
treatment
remdesivir
repurpos
drug
develop
target
rdrp
show
improv
clinic
outcom
report
clinic
trial
underway
consid
work
part
global
effort
respond
time
fashion
fight
deadli
communic
diseas
awar
similar
model
screen
repurpos
exercis
target
pro
report
announc
method
overlap
share
common
result
studi
extend
result
folder
contain
follow
extend
data
tab
sequenc
homolog
pro
cleavag
junction
sarscov
tab
result
virtual
screen
drug
activ
site
pro
crystal
structur
fig
pptx
structur
model
pro
proteas
compar
crystaldocx
comparison
figur
activ
site
model
chain
b
crystal
structur
data
avail
term
creativ
common
zero
right
reserv
data
waiver
public
domain
dedic
applic
statist
analysi
interpret
appropri
ye
detail
dock
provid
bind
energi
cutoff
use
hit
report
tabl
use
catalyt
activ
dimer
consid
virtual
screen
b
top
scorer
mean
extend
data
virtual
screen
one
compound
could
multipl
entri
differ
zinc
number
exampl
hesperidin
correspond
least
differ
compound
differ
differ
result
assembl
tabl
clear
pleas
columnbycolumn
comparison
differ
site
sarscov
also
pleas
add
onelett
amino
acid
code
residu
construct
protein
structur
similar
recent
solv
crystal
structur
confirm
predict
model
good
within
experiment
error
dock
result
seem
differ
significantli
could
author
explain
sourc
data
underli
result
avail
ensur
full
reproduc
ye
compet
interest
disclos
compet
interest
confirm
read
submiss
believ
appropri
level
expertis
confirm
accept
scientif
standard
